verteporfin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
benzoporphyrin derivatives	2816	129497-78-5

Description:

Molecule	Description
Synonyms: verteporphin verteporfin trans-18-Ethenyl-4,4a-dihydro-3,4-bis(methoxycarbonyl)-4a,8,14,19-tetramethyl-23H,25H-benzo[b]porphine-9,13-dipropanoic acid monomethyl ester (1:1 mixture of two regioisomers) visudyne BPD-MA	A benzoporphyrin derivative that is used in PHOTOCHEMOTHERAPY to treat wet type MACULAR DEGENERATION. Molecular weight: 1437.61 Formula: C82H84N8O16 CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: 173.56 ALOGS: ROTB: None

Molecule

Description

Synonyms:

verteporphin
verteporfin
trans-18-Ethenyl-4,4a-dihydro-3,4-bis(methoxycarbonyl)-4a,8,14,19-tetramethyl-23H,25H-benzo[b]porphine-9,13-dipropanoic acid monomethyl ester (1:1 mixture of two regioisomers)
visudyne
BPD-MA

A benzoporphyrin derivative that is used in PHOTOCHEMOTHERAPY to treat wet type MACULAR DEGENERATION.

Molecular weight: 1437.61
Formula: C82H84N8O16
CLOGP:
LIPINSKI: None
HAC: None
HDO: None
TPSA: 173.56
ALOGS:
ROTB: None

Drug dosage:

None

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
July 27, 2000	EMA
April 12, 2000	FDA	VALEANT LUXEMBOURG

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Visual acuity reduced	693.21	52.12	140	993	21686	63466203
Retinal haemorrhage	280.75	52.12	52	1081	4917	63482972
Choroidal neovascularisation	253.44	52.12	33	1100	286	63487603
Retinal pigment epithelial tear	181.58	52.12	24	1109	235	63487654
Polypoidal choroidal vasculopathy	153.51	52.12	18	1115	56	63487833
Subretinal fluid	105.25	52.12	16	1117	446	63487443
Retinal oedema	98.59	52.12	16	1117	685	63487204
Disease progression	97.09	52.12	46	1087	122712	63365177
Detachment of retinal pigment epithelium	84.81	52.12	13	1120	383	63487506
Macular scar	74.70	52.12	10	1123	108	63487781
Retinal depigmentation	73.23	52.12	11	1122	282	63487607
Metamorphopsia	70.82	52.12	13	1120	1150	63486739
Vitreous haemorrhage	69.38	52.12	14	1119	2036	63485853
Maculopathy	62.19	52.12	13	1120	2249	63485640
Retinal pigment epitheliopathy	59.07	52.12	9	1124	254	63487635
Retinal degeneration	54.52	52.12	10	1123	879	63487010

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Visual acuity reduced	1032.68	114.46	217	1379	15932	34939403
Retinal haemorrhage	775.71	114.46	142	1454	4947	34950388
Choroidal neovascularisation	389.05	114.46	52	1544	188	34955147
Polypoidal choroidal vasculopathy	354.29	114.46	46	1550	124	34955211
Detachment of retinal pigment epithelium	287.72	114.46	44	1552	476	34954859
Disease progression	281.99	114.46	123	1473	107954	34847381
Retinal pigment epithelial tear	265.96	114.46	38	1558	245	34955090
Vitreous haemorrhage	239.22	114.46	47	1549	2326	34953009
Retinal degeneration	156.40	114.46	26	1570	490	34954845
Retinal detachment	139.13	114.46	35	1561	5356	34949979
Macular oedema	132.96	114.46	30	1566	2884	34952451
Subretinal fibrosis	130.26	114.46	18	1578	87	34955248

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Visual acuity reduced	1648.97	54.66	336	2312	29133	79712607
Retinal haemorrhage	968.84	54.66	176	2472	8041	79733699
Choroidal neovascularisation	655.54	54.66	86	2562	388	79741352
Polypoidal choroidal vasculopathy	504.00	54.66	63	2585	174	79741566
Disease progression	372.82	54.66	160	2488	184202	79557538
Detachment of retinal pigment epithelium	349.23	54.66	53	2595	763	79740977
Retinal pigment epithelial tear	345.39	54.66	49	2599	427	79741313
Vitreous haemorrhage	275.11	54.66	54	2594	3659	79738081
Retinal degeneration	187.22	54.66	33	2615	1233	79740507
Subretinal fluid	186.92	54.66	31	2617	801	79740939
Retinal detachment	185.13	54.66	46	2602	9201	79732539
Retinal oedema	182.33	54.66	31	2617	934	79740806
Subretinal fibrosis	169.40	54.66	23	2625	139	79741601
Macular oedema	165.47	54.66	38	2610	5436	79736304
Metamorphopsia	147.17	54.66	27	2621	1266	79740474
Retinal depigmentation	115.62	54.66	18	2630	307	79741433
Macular degeneration	110.85	54.66	32	2616	11264	79730476
Macular hole	105.48	54.66	19	2629	802	79740938
Retinal pigment epitheliopathy	94.85	54.66	16	2632	458	79741282
Macular scar	93.82	54.66	13	2635	93	79741647
Retinal disorder	88.16	54.66	19	2629	2028	79739712
Maculopathy	87.41	54.66	20	2628	2805	79738935
Choroidal infarction	86.65	54.66	13	2635	171	79741569
Retinal exudates	85.56	54.66	17	2631	1218	79740522
Choroidal haemorrhage	72.03	54.66	11	2637	164	79741576
Retinal scar	68.90	54.66	12	2636	416	79741324
Visual field defect	60.16	54.66	19	2629	9026	79732714
Retinal ischaemia	55.50	54.66	11	2637	777	79740963
Eye haemorrhage	54.70	54.66	18	2630	9739	79732001

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	S01LA01	SENSORY ORGANS OPHTHALMOLOGICALS OCULAR VASCULAR DISORDER AGENTS Antineovascularisation agents
FDA PE	N0000009801	Photosensitizing Activity
FDA MoA	N0000010217	Photoabsorption
FDA EPC	N0000175540	Photoenhancer
MeSH PA	D003879	Dermatologic Agents
MeSH PA	D017319	Photosensitizing Agents
MeSH PA	D011838	Radiation-Sensitizing Agents
CHEBI has role	CHEBI:35610	antineoplastic agents
CHEBI has role	CHEBI:47868	photosensitising agent
CHEBI has role	CHEBI:88230	autophagy inhibitors

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Choroidal retinal neovascularization	indication	75971007
Exudative age-related macular degeneration	indication	414173003	DOID:10873
Ocular histoplasmosis syndrome	indication	416770009
Pathologic Myopia	indication
Disease of liver	contraindication	235856003	DOID:409
Breastfeeding (mother)	contraindication	413712001
Porphyria	contraindication	418470004

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

ID	Source
4021216	VUID
N0000148662	NUI
D01162	KEGG_DRUG
4021216	VANDF
C0387288	UMLSCUI
CHEBI:32293	CHEBI
CHEMBL2218885	ChEMBL_ID
D000077362	MESH_DESCRIPTOR_UI
DB00460	DRUGBANK_ID
7145	INN_ID
0X9PA28K43	UNII
118886	RXNORM
31931	MMSL
8841	MMSL
d04533	MMSL
008219	NDDF
125708009	SNOMEDCT_US
387059006	SNOMEDCT_US
5362420	PUBCHEM_CID

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Visudyne	HUMAN PRESCRIPTION DRUG LABEL	1	0187-5600	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	15 mg	INTRAVENOUS	NDA	26 sections
Visudyne	HUMAN PRESCRIPTION DRUG LABEL	1	0187-5600	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	15 mg	INTRAVENOUS	NDA	26 sections
Visudyne	HUMAN PRESCRIPTION DRUG LABEL	1	24208-560	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	15 mg	INTRAVENOUS	NDA	25 sections
Visudyne	HUMAN PRESCRIPTION DRUG LABEL	1	50236-001	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	15 mg	INTRAVENOUS	NDA	15 sections